<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">RUDN Journal of Medicine</journal-id><journal-title-group><journal-title xml:lang="en">RUDN Journal of Medicine</journal-title><trans-title-group xml:lang="ru"><trans-title>Вестник Российского университета дружбы народов. Серия: Медицина</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2313-0245</issn><issn publication-format="electronic">2313-0261</issn><publisher><publisher-name xml:lang="en">Peoples’ Friendship University of Russia named after Patrice Lumumba (RUDN University)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">25434</article-id><article-id pub-id-type="doi">10.22363/2313-0245-2021-25-1-25-30</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>CORONAVIRUS INFECTION, INFECTIOUS DISEASES</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>КОРОНАВИРУСНАЯ ИНФЕКЦИЯ, ИНФЕКЦИОННЫЕ БОЛЕЗНИ</subject></subj-group><subj-group subj-group-type="article-type"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Indomethacin &amp; SARS-CoV-2: Prospects for clinical management of the inflammatory state</article-title><trans-title-group xml:lang="ru"><trans-title>Индометацин и SARS-CoV-2: перспективы терапии воспаления в клинике</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kodidala</surname><given-names>Satyanath R.</given-names></name><name xml:lang="ru"><surname>Кодидала</surname><given-names>Сатьянатх Р.</given-names></name></name-alternatives><email>ksatyanath1989@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Sorout</surname><given-names>J.</given-names></name><name xml:lang="ru"><surname>Сороут</surname><given-names>Дж.</given-names></name></name-alternatives><email>ksatyanath1989@gmail.com</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Jayachandra</surname><given-names>S.</given-names></name><name xml:lang="ru"><surname>Джаячандра</surname><given-names>С.</given-names></name></name-alternatives><email>ksatyanath1989@gmail.com</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Narapogu</surname><given-names>V.</given-names></name><name xml:lang="ru"><surname>Нарапогу</surname><given-names>В.</given-names></name></name-alternatives><email>ksatyanath1989@gmail.com</email><xref ref-type="aff" rid="aff3"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">K.D. Medical College, Hospital and Research Centre</institution></aff><aff><institution xml:lang="ru">К.Д. Медицинский колледж, клиника и исследовательский центр</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Zydus Medical College</institution></aff><aff><institution xml:lang="ru">Медицинский колледж Зидус</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Government Medical College</institution></aff><aff><institution xml:lang="ru">Государственный медицинский колледж</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2021-01-12" publication-format="electronic"><day>12</day><month>01</month><year>2021</year></pub-date><volume>25</volume><issue>1</issue><issue-title xml:lang="en">CORONAVIRUS INFECTION, INFECTIOUS DISEASES</issue-title><issue-title xml:lang="ru">КОРОНАВИРУСНАЯ ИНФЕКЦИЯ, ИНФЕКЦИОННЫЕ БОЛЕЗНИ</issue-title><fpage>25</fpage><lpage>30</lpage><history><date date-type="received" iso-8601-date="2021-01-12"><day>12</day><month>01</month><year>2021</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2021, Kodidala S.R., Sorout J., Jayachandra S., Narapogu V.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2021, Кодидала С.Р., Сороут Д., Джаячандра С., Нарапогу В.</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="en">Kodidala S.R., Sorout J., Jayachandra S., Narapogu V.</copyright-holder><copyright-holder xml:lang="ru">Кодидала С.Р., Сороут Д., Джаячандра С., Нарапогу В.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">http://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://journals.rudn.ru/medicine/article/view/25434">https://journals.rudn.ru/medicine/article/view/25434</self-uri><abstract xml:lang="en"><p>Severe acute respiratory syndrome - (SARS) is a pandemic (called as SARS-CoV-2 or COVID-19), severely affected by transmission and fatal disease caused by unknown coronavirus family of RNA virus (SARS-COV). Humans are under great threat among other species were non-identified. Phenotype can range from asymptomatic to fulminate cytokine storm which leads multiorgan failure resulting death. Still the world is eagerly waiting for antiviral drug to stop the corona virus infection. Previous studies found that indomethacin had ability to inhibit the RNA and DNA virus replication. Objectives . Interleukins (IL), Interferons (IFN) and metabolites like «cyclopentane cyclooxygenase» (COX 1/COX 2) are active against several RNA viruses. Experts have divided the SARS infection in three phases (Phase-1, 2, 3) based on severity of infection. In phase-3 there was «cytokine storm» due to exuberant inflammation observed which can damage organs and even fatal. We investigated that effect of indomethacin on COX inhibitor on coronavirus replication and cytokine storm in reducing the hyper inflammatory state. In this article we tried to assess the clinical management of inflammation due to SARS-COV-2 by Indomethacin. Results . Indomethacin can cause relief from the pain on taking deep breath in corona virus infected patients. Indomethacin can be considered safe and effective for prevention and treatment of coronavirus infection also antiviral activity. Conclusion : Indomethacin is a potent inhibitor of SARS CoV-2.</p></abstract><trans-abstract xml:lang="ru"><p>Тяжелый острый респираторный синдром (SARS) - это пандемия (называемая SARS-CoV-2 или COVID-19), вызванная неизвестным семейством коронавирусов РНК-вируса (SARS-COV). Фенотип может варьироваться от бессимптомного до молниеносного цитокинового шторма, который приводит к полиорганной недостаточности и смерти. Тем не менее мир с нетерпением ждет, когда противовирусный препарат остановит заражение вирусом короны. Предыдущие исследования показали, что индометацин обладает способностью подавлять репликацию РНК и ДНК-вирусов. Цель . Интерлейкины (IL), интерфероны (IFN) и метаболиты, такие как «циклопентанциклооксигеназа» (COX 1 / COX 2), активны против нескольких вирусов РНК. Эксперты разделили инфекцию SARS на три фазы (фазы 1, 2, 3) в зависимости от степени тяжести инфекции. В фазе 3 наблюдался «цитокиновый шторм» из-за сильного воспаления, которое могло повредить органы и даже привести к летальному исходу. Мы исследовали влияние индометацина на ингибитор ЦОГ на репликацию коронавируса и цитокиновый шторм в снижении гипервоспалительного состояния. В этой статье мы попытались оценить клиническое лечение воспаления, вызванного SARS-COV-2, с помощью индометацина. Полученные результаты. Индометацин может облегчить боль при глубоком вдохе у пациентов, инфицированных вирусом короны. Индометацин можно считать безопасным и эффективным для профилактики и лечения коронавирусной инфекции, а также противовирусной активностью. Выводы . Индометацин - мощный ингибитор SARS CoV-2.</p></trans-abstract><kwd-group xml:lang="en"><kwd>Indomethacin</kwd><kwd>inflammation</kwd><kwd>COVID-19</kwd><kwd>SARS-COV 2</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>индометацин</kwd><kwd>воспаление</kwd><kwd>COVID-19</kwd><kwd>SARS-COV2</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Zhou P, Yang X-L, Wang X-G, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020:10.1038/s41586-41020-42012-41587.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Xu H, Zhong L, Deng J, et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J Oral Sci. 2020;12(1):8.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Cao Y, Li L, Feng Z, et al. Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations. Cell Discovery. 2020;6(1). doi: 10.1038/s41421020-0147-1.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Shi Y, Wang Y, Shao C, Huang J, Gan J, Huang X, Bucci E, Piacentini M, Ippolito G, Melino G. COVID-19 infection: the perspectives on immune responses. Cell Death Differ. 2020;27(5):1451-1454. doi: 10.1038/s41418-020-0530-3.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Arend W.P. Interleukin-1 receptor antagonist. Adv Immunol. 1993;54:167-227.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Burger D, Chicheportiche R, Giri JG, Dayer JM. The inhibitory activity of human interleukin-1 receptor antagonist is enhanced by type II interleukin-1 soluble receptor and hindered by type I interleukin-1 soluble receptor. J Clin Invest. 1995;96:38-41.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Conti P, Ronconi G, Caraffa A, Gallenga CE, Ross R, Frydas I, Kritas SK. Induction of pro- inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. Masters P.S., Perlman, S. Coronaviridae. In: Knipe D.M., Howley P. (eds) Fields Virology. Lippincott Williams and Wilkins, Philadelphia, PA. 2013:825- 858.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Brunton LL, Parker L, Blumenthal DK, Buxton ILO. Goodman and Gilman’s Manual of Pharmacology and Therapeutics. New York: McGraw-Hill Medical, 2008:446-47.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Amici C, Di Caro A, Ciucci A, et al. Indomethacin has a potent antiviral activity against SARS coronavirus. Antivir Ther. 2006;11:1021-30. https://hospitalhealthcare.com/covid-19/indomethacin-has-a-positive-impact-on-covid-19-symptoms.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Brunton LL, Parker L, Blumenthal DK, Buxton ILO. Goodman and Gilman’s Manual of Pharmacology and Therapeutics. New York, NY: McGraw. Hill Medical. 2008:446- 447.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Day M. Covid-19: ibuprofen should not be used for managing symptoms say doctors and scientists. BMJ. 2020;19:m1086.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Gupta R, Misra A. Contentious issues and evolving concepts in the clinical presentation and management of patients with COVID-19 infection with reference to use of therapeutic and other drugs used in co-morbid diseases (Hypertension, diabetes, etc.). Diabetes Metab Syndr. 2020;14:251-254.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Updated: WHO now doesn’t recommend avoiding ibuprofen for COVID-19 symptoms. https://www.sciencealert.com/whorecommends-to-avoid-taking-ibuforfin-for-covid-19-symptoms.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Chmiel JF, Konstan MW, Accurso FJ, et al. Use of ibuprofen to assess inflammatory biomarkers in induced sputum: implications for clinical trials in cystic fibrosis. J Cyst Fibros. 2015;14:720-726.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Zhang W., Zhao Y., Zhang F., et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the perspectives of clinical immunologists from China. Clin Immunol. 2020;214:108393.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Lucas S. The Pharmacology of Indomethacin. Headache. 2016 Feb;56(2):436-46.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Draper MP, Martell RL, Levy SB. Indomethacin-mediated reversal of multidrug resistance and drug efflux in human and murine cell lines overexpressing MRP, but not P-glycoprotein. Br. J. Cancer. 1997;75(6):810-5.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Vane JR, Botting RM. Mechanism of action of antiinflammatory drugs. Adv Exp Med Biol. 1997;433:131-138.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Tegerder I, Pfeilschifter J, Geisslinger G. Cyclooxygenase- independent actions of cyclooxygenase inhibitors. FASEB J. 2001;15:2057-2072.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Amici C, La Frazia S, Brunelli C, Balsamo M, Angelini M, Santoro MG. Inhibition of viral protein translation by indomethacin in vesicular stomatitis virus infection: role of eIF2α kinase PKR. Cell. Microbiol. 2015;17(9):1391-404.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Hoppmann RA, Peden JG, Ober SK. Central nervous system side effects of nonsteroidal anti-inflammatory drugs. Aseptic meningitis, psychosis, and cognitive dysfunction. Arch. Intern. Med. 1991;151(7):1309-13.</mixed-citation></ref></ref-list></back></article>
